Answers are grounded in this paper and cite their sources.
One-electron reduction of the complex [(TPyA)2Fe(II)2((NPh)L(2-))](2+) (TPyA = tris(2-pyridylmethyl)amine, (NPh)LH2 = azophenine = N,N',N",N'''-tetraphenyl-2,5-diamino-1,4-diiminobenzoquinone) affords the complex [(TPyA)2Fe(II)2((NPh)L(3-•))](+). X-ray diffraction and Mössbauer spectroscopy confirm that the reduction occurs on (NPh)L(2-) to give an S = 1/2 radical bridging ligand. Dc magnetic susceptibility measurements demonstrate the presence of extremely strong direct antiferromagnetic exchange between S = 2 Fe(II) centers and (NPh)L(3-•) in the reduced complex, giving an S = 7/2 ground state with an estimated coupling constant magnitude of |J| ≥ 900 cm(-1). Mössbauer spectroscopy and ac magnetic susceptibility reveal that this complex behaves as a single-molecule magnet with a spin relaxation barrier of U(eff) = 50(1) cm(-1). To our knowledge, this complex exhibits by far the strongest magnetic exchange coupling ever to be observed in a single-molecule magnet.
No takes yet. Share an insight, caveat, or question.
Jeon et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: